3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
8
Melanoma
6
Head and Neck Neoplasms
6
Colonic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Urinary Bladder Neoplasms
4
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Carcinoma, Hepatocellular
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Neoplasms
3
Carcinoma, Merkel Cell
3
Adenocarcinoma
3
Rectal Neoplasms
2
Prostatic Neoplasms
2
Kidney Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Uterine Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Lung Neoplasms
1
Interventions
Sorafenib
68
Bevacizumab
44
Oxaliplatin
25
Doxorubicin
22
Gemcitabine
21
Fluorouracil
21
Radiosurgery
20
Nivolumab
19
durvalumab
18
Radiofrequency Ablation
18
pembrolizumab
17
lenvatinib
17
Cisplatin
17
Capecitabine
17
atezolizumab
14
Leucovorin
14
Hepatectomy
14
Radiotherapy
12
tremelimumab
10
Irinotecan
10
Drug Therapy
10
Cyclophosphamide
10
Carboplatin
10
Blood Specimen Collection
10
Ipilimumab
9
regorafenib
8
Liver Transplantation
8
Everolimus
8
Cryosurgery
8
Chemotherapy, Adjuvant
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
cemiplimab
×
Gastrointestinal
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled